Document |
Document Title |
WO/2019/033164A1 |
A method for demethylating a methylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C1-...
|
WO/2019/033168A1 |
method for decarboxylating a carboxylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C...
|
WO/2019/027040A1 |
A compound represented by formula (1) (in the formula, R1-R8, R11-R18, R21-R28, R31-R38, X, Y, L1, L2, L3, and Ar are as defined in the specification) provides an organic electroluminescent element having a low drive voltage and exceptio...
|
WO/2019/027263A1 |
The present application provides a heterocyclic compound represented by Chemical Formula 1, and an organic light-emitting element including same.
|
WO/2019/023803A1 |
Powdered cannabis extracts and methods for obtaining powdered cannabis extracts are described. In an aspect, the present application describes a method of preparing a single-serve container which may be configured for receipt in a single...
|
WO/2019/022002A1 |
A compound represented by formula (I) or a salt thereof. (In formula (I), Q1 represents an (un)substituted C6-10 aryl group; Q2 represents an (un)substituted C1-6 alkyl group, an (un)substituted C6-10 aryl group, or a five- to ten-member...
|
WO/2019/019792A1 |
The present invention relates to a coumarin (ketone) oxime ester compound of formula (I), wherein the n and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compound has a very strong ultraviolet absorption in a range...
|
WO/2019/020738A1 |
The present invention describes a process for the production of (-)-cannabidiol (CBD) from industrial hemp by means of an extraction followed by two alternative working processes: a process A which provides extraction with solvents first...
|
WO/2019/018455A1 |
Methods of treating autoimmune microvascular conditions using diosmin or diosmetin are described, particularly the treatment of digital ulcers in systemic sclerosis.
|
WO/2019/013542A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.
|
WO/2019/012166A1 |
Compounds with a drimenyloxyarene structure and derivatives, and the use thereof to treat infections caused by phytopathogenic fungi, as fungistatic agents with a low ecological impact. The present invention comprises compounds with the ...
|
WO/2019/013249A1 |
A chromene compound showing a reduced matrix dependency and having at least one indenonaphthopyran structure which carries a group forming a spiro ring together with the carbon atom at the 13-position, wherein the indenonaphthopyran stru...
|
WO/2019/013526A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light emitting device comprising the same.
|
WO/2019/012000A1 |
The present invention relates to a novel synthetic pathway for alpha- tocopherol. The invention discloses different reactions yielding some new intermediates in a very high yield and stereoselectivity.
|
WO/2019/009257A1 |
The problem to be solved by the present invention is to provide a method for producing a flavone having a malonyl group added to glucose located at position-7 therein using a polynucleotide encoding a protein having an activity to transf...
|
WO/2019/008537A1 |
There is provided a medical compound comprising a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below: Formula (I) wherein at least two of R2-R6 a re H, and the remaining ar...
|
WO/2019/007447A1 |
The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumours in the bone and surrounding tissue...
|
WO/2019/010419A1 |
A method for purification and separation of cannabinoids, such as cannabidiol and tetrahydrocannabinol, e.g., from the dried hemp and cannabis leaves can use a continuous simulated moving bed process and a combination of one or more of a...
|
WO/2019/004790A1 |
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting element including same.
|
WO/2019/004612A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
WO/2019/004791A1 |
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting element including same.
|
WO/2019/004796A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
WO/2018/236913A1 |
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...
|
WO/2018/233696A1 |
Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclose...
|
WO/2018/234643A1 |
The present invention concerns type II photoinitiators for the free-radical crosslinking of silicone compositions, in particular acrylic silicone compositions. The present invention concerns a silicone composition C1 that can be crosslin...
|
WO/2018/232527A1 |
The present invention describes complex topical aqueous compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic...
|
WO/2018/233483A1 |
Provided are phenylquinolinone and flavonoid derivatives and preparation methods therefor, wherein the derivatives are histamine H3 receptor antagonists, which can protect and restore the normal function of the central nervous system; an...
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
WO/2018/230936A1 |
The present invention relates to a composition for treating metabolic diseases containing a novel compound or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, unlike the PPARγ agonist rosiglitazone, whi...
|
WO/2018/229665A1 |
The present invention relates to novel spirobibenzopyran conjugate derivatives with potent anti- cancer activity as pharmaceutical agents, their stereoisomers, their polymorphs and their pharmaceutically acceptable salts and their pharma...
|
WO/2018/229261A1 |
The invention relates to a prodrug compound consisting of a drug moiety comprising an amine or hydroxyl moiety and a protecting group moiety covalently linked to the amine or hydroxyl moiety. The drug moiety is effective in the treatment...
|
WO/2018/225093A1 |
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (IIIQ): wherein X6', a, b, C8', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82'...
|
WO/2018/225520A1 |
Provided are: a compound represented by general formula (i); and a composition and a liquid crystal display element which use said compound. The compound represented by general formula (i) is obtained by reacting a compound represented b...
|
WO/2018/225482A1 |
The purpose of the present invention is to provide a material which has an excellent ammonia metabolism improving effect and is effective for endurance improvement, fatigue resistance, etc. This ammonia metabolism promoter has catechins ...
|
WO/2018/218281A1 |
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.
|
WO/2018/221543A1 |
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph
thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...
|
WO/2018/214639A1 |
Disclosed are a 2-azacyclo-5-trifluoromethyl-8-nitrobenzo(thio)pyran-4-one compound, a preparation method therefor and the use thereof in a drug for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. In ...
|
WO/2018/212216A1 |
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...
|
WO/2018/209425A1 |
A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of na...
|
WO/2018/205286A1 |
Provided is a conjugate containing a fluorescent chromophore, which has any structure selected from C1 to C3. The conjugate containing the fluorescent chromophore provided by the present invention comprises one fluorescent chromophore an...
|
WO/2018/205038A1 |
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...
|
WO/2018/206096A1 |
The present invention relates to photochromic indeno fused phenanthrenopyran compounds represented by the following Formula (I). With some embodiments, the photochromic compounds represented by Formula (I) include at least one lengthenin...
|
WO/2018/205846A1 |
A method for extracting highly-effective natural plant anthocyanidin, which relates to the technical field of bioengineering. The method comprises the steps of: hydrolyzing anthocyanin; by using sodium bicarbonate or potassium bicarbonat...
|
WO/2018/199287A1 |
The present disclosure provides: a composition for treating and/or preventing crystalline retinopathy, the composition containing a cholesterol accumulation inhibitor; a method for treating and/or preventing crystalline retinopathy, the ...
|
WO/2018/194172A1 |
The present invention addresses the problem of providing a tricine derivative having higher antiviral activity. The compound according to the present invention is a compound represented by formula (I) or a salt thereof. (In formula (I), ...
|
WO/2018/190666A1 |
The present specification relates to a heterocyclic compound represented by chemical Formula 1, and an organic light-emitting element including same.
|
WO/2018/189210A1 |
The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these ...
|
WO/2018/191594A1 |
A method for treating a condition characterized by excessive adipose tissue in a subject, the method comprising administering to said subject a compound that inhibits adipogenesis and/or induces adipocyte apoptosis in said excessive adip...
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
WO/2018/183800A1 |
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and substituted (4'-hydroxylphenyl)cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be ...
|